Engineering of BZ transposase and transposon donor vector for enhanced efficiency and safety in gene delivery applications
Nucleic Acids Research · 2025
DOI: 10.1093/nar/gkaf935 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, 2025. Verfasst von Saisai Wang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Lab of Transposon, College of Animal Science and Technology, Yangzhou University, Yangzhou 225009, China. Hauptthemen laut MEDLINE: DNA Transposable Elements, Transposases, Genetic Vectors, Gene Transfer Techniques. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Shanghai Science and Technology Innovation Action Plan, Cell and Gene Therapy Project.
Abstract (Originalsprache)
Transposons, as non-viral vectors, provide an efficient and secure method for stable gene delivery and have been successfully applied in human gene therapies. The engineering of transposase has significantly improved the efficiency of various transposon systems, including chimeric antigen receptor (CAR)-T cell engineering. In this study, multiple engineering strategies were implemented to enhance the efficiency and safety of the Baize (BZ) transposon system, which was derived from the ZB (the wild-type BZ, BZwt) and has been proven to be an effective tool for genetic manipulation in vertebrates. Through designed engineering and combinatorial mutagenesis in vitro, several hyperactive BZ transposase variants with higher transposition activity, cargo capacity, and integration safety were developed. At optimal activity levels, BZ325 surpassed BZwt by ∼1.2-fold and 2.3-fold at 500 ng and 10 ng dosages of donor plasmids, respectively. Furthermore, reducing the size of BZ donor vector backbone significantly increased CAR-T modification efficiency without compromising its function. Notably, BZ325, BZ326, and especially BZ327 exhibited significantly higher CAR-T engineering rates and CAR expression levels than BZwt. Overall, the engineering of the BZ transposon system significantly enhanced its transposition activity, cargo capacity, and safety, providing a compelling tool for gene transfer applications and emphasizing its potential in gene therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Lab of Transposon, College of Animal Science and Technology, Yangzhou University, Yangzhou 225009, China.
- Biological Therapy Center, Shanghai Mengchao Cancer Hospital, Shanghai University, Shanghai 201805, China.
- Nucleic Acid Research Center, Shanghai Cell Therapy Group Co., Ltd, Shanghai 201805, China.
- Cell Therapy Innovation Research Institute, School of Medicine, Shanghai University, Shanghai 200444, China.
ORCID-Profile: Chengyi Song
Förderung
- National Natural Science Foundation of China
- Shanghai Science and Technology Innovation Action Plan
- Cell and Gene Therapy Project
- Science and Technology Commission of Shanghai Municipality
Zitieren
APA
Wang, S., Zhang, P., Sun, Y., Fang, Y., Wang, P., Shao, M., Zhang, N., Shi, S., Chen, X., Gao, H., Cheng, J., Gao, B., Liu, T., Qian, Q., & Song, C. (2025). Engineering of BZ transposase and transposon donor vector for enhanced efficiency and safety in gene delivery applications. Nucleic Acids Research. https://doi.org/10.1093/nar/gkaf935
Vancouver
Wang S, Zhang P, Sun Y, Fang Y, Wang P, Shao M, et al. Engineering of BZ transposase and transposon donor vector for enhanced efficiency and safety in gene delivery applications. Nucleic Acids Research. 2025. doi:10.1093/nar/gkaf935
BibTeX
@article{Wang2025,
author = {Wang, Saisai and Zhang, Pingjing and Sun, Yan and Fang, Yuan and Wang, Pei and Shao, Meiqi and Zhang, Ningning and Shi, Shasha and Chen, Xin and Gao, Haixia and Cheng, Jingbo and Gao, Bo and Liu, Tao and Qian, Qijun and Song, Chengyi},
title = {Engineering of BZ transposase and transposon donor vector for enhanced efficiency and safety in gene delivery applications},
journal = {Nucleic Acids Research},
year = {2025},
doi = {10.1093/nar/gkaf935}
}
EUVIMED